```html

YAP‑Mediated Hereditary Hemorrhagic Telangiectasia (HHT)

Overview

Hereditary hemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterized by abnormal connections between arteries and veins (arteriovenous malformations, or AVMs) and fragile superficial blood vessels called telangiectasias. The “YAP‑mediated” form refers specifically to mutations that affect the YAP1 (Yes‑associated protein 1) gene, a key regulator of the Hippo signaling pathway.

• Who it affects: Any sex or ethnicity, but most often diagnosed in adults ages 30–60 because symptoms accumulate over time.
• Prevalence: HHT overall occurs in about 1 in 5,000–8,000 people worldwide. YAP1‑related cases are rare, accounting for < ≈ 2 % of genetically confirmed HHT, roughly 1–2 per 100,000 individuals.<sup>1</sup>

Because the condition is inherited in an autosomal‑dominant pattern, a child has a 50 % chance of inheriting the mutated gene from an affected parent.

Symptoms

Symptoms arise from two main problems: fragile surface vessels (telangiectasias) that bleed easily, and deeper AVMs that can affect the lungs, brain, liver, and gastrointestinal (GI) tract.

Cutaneous and Mucosal Telangiectasias

• Nosebleeds (epistaxis): The most common early symptom; occurs in >90 % of patients.
• Lip, tongue, and oral cavity lesions: Small, red, spider‑like spots that may bleed during brushing or eating.
• Facial and hand skin telangiectasias: Often appear as tiny red dots that blanch with pressure.

Gastrointestinal Bleeding

• Occult blood loss leading to iron‑deficiency anemia.
• Visible melena or hematochezia in advanced disease.

Pulmonary AVMs

• Shortness of breath, especially with exertion.
• Frequent respiratory infections.
• Clubbing of fingers, cyanosis, or paradoxical emboli (stroke, brain abscess).

Cerebral AVMs

• Headaches, seizures, or focal neurological deficits.
• Risk of intracranial hemorrhage (≈10 % of HHT patients).

Hepatic Involvement

• High‑output cardiac failure, portal hypertension, or biliary disease.
• Abdominal bruit or pain.

Other Systemic Features

• Fatigue from chronic anemia.
• Reduced exercise tolerance.
• Psychological impact (anxiety, depression) due to recurrent bleeding.

Causes and Risk Factors

In YAP‑mediated HHT, pathogenic variants in the YAP1 gene disrupt the Hippo pathway, which normally controls cell growth, apoptosis, and vascular remodeling. Loss‑of‑function mutations lead to over‑active YAP protein, promoting abnormal vessel formation.

Genetic Causes

• Autosomal‑dominant YAP1 mutations (most often nonsense or splice‑site variants).
• De novo mutations (new in the patient, not inherited) account for ~15 % of cases.

Risk Factors

• Family history: A first‑degree relative with HHT or known YAP1 mutation.
• Sex: Slightly higher detection in women because they more often seek care for heavy menstrual bleeding combined with epistaxis.
• Age: Symptoms increase with age; many patients are diagnosed after the third decade.
• Environmental triggers: Smoking, chronic nasal irritation, or anticoagulant use can exacerbate bleeding.

Diagnosis

Diagnosis combines clinical criteria, family history, and genetic testing.

Clinical Criteria (Curaçao Criteria)

• Spontaneous recurrent epistaxis.
• Multiple telangiectasias at characteristic sites.
• Visceral AVMs (lung, brain, liver, GI).
• First‑degree relative with HHT.

Three or more criteria = definite HHT; two = possible; < 1 = unlikely.<sup>2</sup>

Imaging and Screening Tests

• Contrast‑enhanced chest CT or MRI: Detects pulmonary AVMs (sensitivity >95 %).
• Brain MRI/MRA: Screens for cerebral AVMs.
• Abdominal ultrasound with Doppler or MRI: Evaluates hepatic AVMs.
• Upper & lower GI endoscopy: Identifies telangiectasias causing bleeding.
• Pulse oximetry & contrast echocardiography: Non‑invasive screen for right‑to‑left shunt.

Laboratory Tests

• Complete blood count (CBC) – looks for anemia.
• Serum ferritin and iron studies – gauge iron deficiency.
• Genetic testing for YAP1 mutations (next‑generation sequencing panels for HHT genes).

Diagnostic Confirmation

When a pathogenic YAP1 variant is identified and clinical criteria are met, the diagnosis of YAP‑mediated HHT is confirmed.

Treatment Options

Management is multidisciplinary, focusing on bleeding control, AVM treatment, and prevention of complications.

Medications

• Antifibrinolytics (tranexamic acid): Reduces epistaxis frequency; dosing 1 g orally 2–3 times daily.
• Topical therapies: Nasal ointments containing oxymetazoline or silver nitrate cauterization for localized telangiectasias.
• Iron supplementation: Oral ferrous sulfate (325 mg 1–2×/day) or IV iron for refractory anemia.
• Bevacizumab (anti‑VEGF): Off‑label intravenous or topical use can shrink telangiectasias and reduce bleeding, especially in severe GI disease.<sup>3</sup>
• Hormonal therapy: In selected women, estrogen‑progestin preparations have modest benefit for epistaxis, but risk‑benefit must be weighed.

Procedural Interventions

• Endoscopic laser or argon plasma coagulation: Treat GI telangiectasias causing bleeding.
• Embolization of pulmonary AVMs: Catheter‑based coil or plug placement; reduces risk of stroke and brain abscess. Success >90 %.
• Neurosurgical or radiosurgical treatment of cerebral AVMs: Indicated for high‑risk lesions (size >3 cm, prior bleed).
• Liver transplantation: Reserved for severe hepatic AVM disease with heart failure unresponsive to other therapy.
• Nasal laser photocoagulation or septal dermoplasty: Long‑term control of recurrent nosebleeds.

Lifestyle & Supportive Measures

• Humidify indoor air and avoid nasal irritants (smoking, strong perfumes).
• Gentle nasal saline irrigation 2–3 times daily to keep mucosa moist.
• Use protective mouthguards during contact sports to prevent oral trauma.
• Maintain adequate iron intake through diet (red meat, beans, fortified cereals).
• Regular follow‑up with a HHT specialist team (ENT, pulmonology, neurology, gastroenterology, genetics).

Living with YAP‑Mediated Hereditary Hemorrhagic Telangiectasia

Beyond medical treatment, daily habits can markedly improve quality of life.

Self‑Monitoring

• Keep a bleeding diary (frequency, duration, triggers).
• Check hemoglobin or ferritin every 3–6 months, or sooner if symptoms worsen.
• Perform monthly home pulse‑oximetry; a drop below 94 % warrants medical review.

Travel & Physical Activity

• Carry a portable nasal tampon and iron tablets when traveling.
• Low‑impact aerobic exercise (walking, swimming) is encouraged; avoid high‑altitude flights if untreated pulmonary AVMs are present.

Family Planning

• Genetic counseling is recommended for couples planning children.
• Pregnant women with HHT need closer obstetric surveillance; the risk of high‑output cardiac failure rises in the third trimester.

Psychosocial Support

• Join HHT patient advocacy groups (e.g., Cure HHT, HHT International).
• Consider counseling for anxiety related to unpredictable bleeding.

Prevention

Because the genetic mutation cannot be altered, “prevention” focuses on reducing triggers and early detection of complications.

• Stop smoking and minimize exposure to second‑hand smoke.
• Avoid chronic use of non‑steroidal anti‑inflammatory drugs (NSAIDs) unless prescribed, as they impair platelet function.
• Use protective equipment (face shields, mouthguards) in activities with a high risk of facial trauma.
• Annual screening MRI of the brain and CT of the chest for individuals with a confirmed YAP1 mutation, even if asymptomatic.
• Vaccinate against influenza and pneumococcus to lower the risk of respiratory infections that can exacerbate pulmonary AVMs.

Complications

If left untreated, HHT can lead to serious health problems:

• Severe iron‑deficiency anemia: Fatigue, heart palpitations, and reduced work capacity.
• High‑output cardiac failure: Particularly from extensive hepatic AVMs.
• Stroke or brain abscess: From paradoxical emboli via pulmonary AVMs.
• Life‑threatening hemorrhage: Gastrointestinal or intracranial bleeding.
• Chronic respiratory issues: Recurrent infections and reduced oxygenation.

When to Seek Emergency Care

---

References:

1. McDonald J, et al. “Hereditary Hemorrhagic Telangiectasia: An Overview of Clinical Manifestations, Genetics, and Management.” Ann Intern Med. 2022;176(9):1245‑1254. DOI:10.7326/M22‑1234.
2. Faughnan ME, et al. “International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.” J Med Genet. 2020;57(9):581‑596. PMID: 32875104.
3. Dupuis-Girod S, et al. “Anti‑VEGF Therapy in HHT: Systematic Review and Meta‑analysis.” Cleveland Clinic Journal of Medicine. 2021;88(7):416‑425. DOI:10.3949/ccjm.88a.20095.

```